The abstract is read at the publisher; the summary is JClub's.
Enterobacter ludwigii LS57, a human-derived swarming strain, reduced weight loss and preserved colon length in DSS-induced colitis while showing no treatment-related safety signals in rats or dogs.
- Why it matters: IBD has major unmet need, and fecal microbiota transplantation is hard to define and manufacture, motivating single-strain live biotherapeutics with clear control strategies.
- What they did: The team completed preclinical CMC for LS57, including a three-tier cell bank, 30 L fed-batch fermentation, and an enteric-coated capsule, then tested safety and efficacy in DSS- and TNBS-induced colitis models.
- The result: LS57 lowered colonic pro-inflammatory cytokines, remodeled gut microbiota, colonized inflamed colon without translocation in wild-type and interleukin-10-deficient mice, and supported clinical development for IBD.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.